Arindam Bose is a scientist at the Dana-Farber Cancer Institute/Harvard Medical School, where his primary area of research is gynecologic malignancy. Arindam has earned his doctoral degree in chemistry from the University of Connecticut, working on DNA damage, mutagenesis, and DNA repair. After finishing his postdoctoral study at the University of Pittsburgh Cancer Institute Dr. Bose has joined Beth Israel Deaconesses Medical Center/Harvard Medical School (BIDMC) as a research fellow in medicine. His strong rigor to work in precision medicine has brought him to Harvard Medical School. At BIDMC his primary goal was to address the challenging questions about therapeutic resistance among pancreatic cancer patients with defective DNA repair pathways. After finishing his fellowship Dr. Bose has joined the Center for DNA Damage and Repair in the Department of Radiation Oncology at the Dana-Farber Cancer Institute/Harvard Medical School as a principal scientist.
Being a translational researcher his research work is focused on deciphering the molecular mechanism of specific DNA damage repair and tolerance pathways to overcome chemoresistance among patients with ovarian cancer. He is implementing new research models to test novel therapeutic combinations based on genetic alterations in DNA repair genes. Using state of the art functional genomics and high-throughput screenings he is trying to bridge bioassay techniques in biology, immunology and analytical chemistry. Dr. Bose is also actively involved in early drug development in collaboration with various bio/pharmaceutical companies and intensely participating in multiple ongoing clinical trials. His new approach of personalized medicine will lead to improved healthcare by predicting the best course of cytotoxic chemotherapy and radiotherapy to foster effective disease management.